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Abstract
Background: There is strong evidence indicating that gut microbiota have the potential to modify, or be modified
by the drugs and nutritional interventions that we rely upon. This study aims to characterize the compositional and
functional effects of several nutritional, neutraceutical, and pharmaceutical cardiovascular disease interventions on
the gut microbiome, through metagenomic and metabolomic approaches. Apolipoprotein-E-deficient mice were
fed for 24 weeks either high-fat/cholesterol diet alone (control, HFC) or high-fat/cholesterol in conjunction with one
of three dietary interventions, as follows: plant sterol ester (PSE), oat β-glucan (OBG) and bile salt hydrolase-active
Lactobacillus reuteri APC 2587 (BSH), or the drug atorvastatin (STAT). The gut microbiome composition was then
investigated, in addition to the host fecal and serum metabolome.
Results: We observed major shifts in the composition of the gut microbiome of PSE mice, while OBG and BSH
mice displayed more modest fluctuations, and STAT showed relatively few alterations. Interestingly, these
compositional effects imparted by PSE were coupled with an increase in acetate and reduction in isovalerate (p < 0.
05), while OBG promoted n-butyrate synthesis (p < 0.01). In addition, PSE significantly dampened the microbial
production of the proatherogenic precursor compound, trimethylamine (p < 0.05), attenuated cholesterol
accumulation, and nearly abolished atherogenesis in the model (p < 0.05). However, PSE supplementation produced
the heaviest mice with the greatest degree of adiposity (p < 0.05). Finally, PSE, OBG, and STAT all appeared to have
considerable impact on the host serum metabolome, including alterations in several acylcarnitines previously
associated with a state of metabolic dysfunction (p < 0.05).
Conclusions: We observed functional alterations in microbial and host-derived metabolites, which may have
important implications for systemic metabolic health, suggesting that cardiovascular disease interventions may have
a significant impact on the microbiome composition and functionality. This study indicates that the gut
microbiome-modifying effects of novel therapeutics should be considered, in addition to the direct host effects.
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Background
Cardiovascular diseases represent the most fatal maladies
of the system-wide metabolic dysfunction observed in mil-
lions globally, currently responsible for an estimated ~30%
of mortalities each year [1]. Circulating low-density
lipoprotein cholesterol (LDL-C) and high-density lipopro-
tein cholesterol (HDL-C) levels are key modifiable
markers in atherosclerosis development and, as a result,
these have been the targets of the vast majority of nutri-
tional and pharmaceutical cardiovascular disease interven-
tions. Although external factors such as physical exercise
and diet play primary roles in cardiovascular disease onset,
it has become evident that the trillions of microorganisms
indigenous to our gut also contribute [2–4]. These bac-
teria and other microbes express a diverse array of genes,
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many of which play important roles in metabolic function
and dysfunction. Such communities respond directly to
the nutritional and pharmaceutical environment that their
host provides them with, and this largely dictates import-
ant host metabolic characteristics such as hormonal and
inflammatory tones [5, 6]. While some of these effects can
have beneficial outcomes for host metabolic health, the
promotion of certain species has even been correlated
with cardiovascular disease pathogenesis (for review [7]).
However, we are now discovering that these microbes
can express enzymes capable of interacting and interfer-
ing with the nutritional and pharmaceutical interven-
tions which we consume, ultimately impacting on their
bioactivity. There is growing appreciation for the gut
microbiome modulating capacity of many functional nu-
tritional ingredients, such as phytosterols [8] and non-
digestible polysaccharides [9, 10], yet this still stems
from a limited number of studies for many ingredients.
On the other hand, a review reportedly identified 30
common drugs which were open to metabolism by bac-
terial enzymes, through proteolysis, reduction, dehy-
droxylation, hydrolysis, and other reactions [11]. The
authors predicted that the number of drug-microbiota
interactions identified would increase rapidly in the
coming years. One drug which appears to act at least in
part through the microbiota is metformin, a widely used
therapeutic for metabolic dysfunction. It was initially
noted that the effects of metformin were compromised by
the application of certain antibiotics; however, more recent
studies have demonstrated an enrichment of Akkermansia
muciniphila in the microbiota of metformin-treated
animals [12], and the corrective effects of Akkermansia
muciniphila in models of metabolic dysfunction have previ-
ously been demonstrated by Everard et al. [13]. Statins, as
one of the most widely consumed drug families globally,
are of considerable interest in this regard.
In addition, several functional food therapeutics have
gained high-quality scientific support in recent years.
Current meta-analyses demonstrate that oat β-glucan
dietary supplementation consistently reduces LDL-C,
non-HDL, and apolipoprotein (apo)-B particles in mod-
erately hyperlipidaemic individuals [14, 15]. While the
reductions are somewhat modest, oat β-glucan supple-
mentation may represent an effective and safe method
for the management of cardiovascular disease risk. In-
deed, it is likely that such functional food ingredients act
through manipulation of the indigenous microbiome
[16]. Another interventional design currently being ex-
plored is the direct application of bacteria expressing an
enzyme of interest, such as the bile salt hydrolase family
[17, 18]. One such organism, which has reached the
market following several successful randomized clinical
trials, is Lactobacillus reuteri NCIMB 30242. The strain
has demonstrated the potential to reduce LDL-C, non-
LDL-C, and apo-B100 [19], as well as several inflamma-
tory markers associated with atherogenesis [20].
The mechanisms of action of widely used functional
foods, and even certain prescribed pharmaceutics, have
traditionally often remained partially unclear. It is likely
that many of these interventions act indirectly on their
intended target by modifying the host gut microbiota, or
being modified by the gut microbiota. It may be import-
ant to elucidate these microbial interactions in order to
personalize patient therapies. In the present study, we
used the apo-E−/− murine model which closely mirrors
the pathophysiology of human atherosclerosis [21]. Apo-
E is essential to the recognition of esterified cholesterol-
rich particles and subsequent cholesterol uptake by
hepatocytes. Without this cycle, an atherogenic lipid
profile will develop and prevail, along with atheroscler-
otic plaque formation. The ultimate purpose of this
study was to characterize the compositional and func-
tional alterations to the microbiome and metabolome
following courses of commercially available nutritional
and pharmaceutical cardiovascular disease interventions.
Methods
Animals and diets
Four-week-old male ApoEtm1Unc/J mice were acquired
from the Jackson Laboratory (JAX, through Charles
River Laboratories International), housed under barrier-
maintained conditions within the Biological Service Unit,
University College Cork. Animals were acclimatized for
2 weeks prior to being randomized into six separate
groups (A-E n = 14, F n = 7). The four intervention
groups were as follows: (A) a bile salt hydrolase-active
probiotic Lactobacillus reuteri APC 2587 (BSH;
109 CFU/day), (B) plant sterol ester (PSE; 3.4% w/w; Rai-
sio), (C) oat β-glucan (OBG; 7% w/w; OatWell), and (D)
atorvastatin (STAT; 1 · 5 mg/kg). All intervention groups
received a high-fat/cholesterol (HFC; 42% fat, 1.25%
cholesterol; Harlan) diet alongside treatment for a 24-
week period. In addition, (E) HFC diet control and (F)
normal chow control (NC) were run concurrently.
Bacteria and culturing
A rifampicin-resistant derivative of BSH was created and
stored in 70% v/v glycerol, at −80 °C. From these stocks,
bacteria were routinely cultured anaerobically at 37 °C
on de Man Rugosa Sharp (MRS; Difco; 1 · 5% w/w agar)
with the addition of 100 μg/ml w/v rifampicin. From
these plates, single colonies were inoculated in 5 ml
MRS-rifampicin broth and grown overnight under the
same conditions. Bacteria were subcultured twice more
prior to freeze-drying.
Bacteria were cultured as above until stationary phase
and centrifuged (16,900 × g for 15 min, at 4 °C; SLA-
3000 rotor, Sorvall RC B5-Plus). The resulting cell pellet
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was washed twice with phosphate buffered saline (Sigma
Aldrich). Cells were then resuspended at ~2 × 1010 CFU/
ml in sterile 15% (w/v) trehalose (Sigma Aldrich), and
1 ml aliquots were dispensed into sterile 2 ml lyophilisa-
tion vials. The vials were lyophilized on a 24-hour pro-
gram (freeze temperature −40 °C, additional freeze
1 min, condenser set point −60, vacuum set point 600
mTorr; VirTis AdVantage Wizard 2·0) and stored at 4 °
C until use. Bacteria were resuspended in distilled water
each day in order to deliver 109 CFU/day to each animal.
Gastric transit of the strains was assessed each week by
culturing serial dilutions of fresh fecal samples on MRS-
rifampicin plates, as described previously.
Biochemical and biometric analysis
At several points during intervention, mice were bled by fa-
cial vein puncture. Whole blood was allowed to clot on ice
for 30 min prior to centrifugation at 1000 × g for 10 min at
4 °C. Serum was withdrawn and stored at −80 °C until use.
Total serum cholesterol levels were determined in duplicate
as per manufacturer’s instructions using the EnzyChrom
colorimetric assay (ECCH-100, BioAssay Systems, Hay-
ward, CA, USA). Serum HDL-C, LDL-C, and triglycerides
(TG) were determined by their respective LabAssay assays
(Wako Diagnostics). Fecal and liver lipids were extracted
from approximately 50 mg of sample with a 2:1 (v:v) mix-
ture of chloroform:methanol according to the method of
Folch et al. [22]. The resulting lipids were dried and resus-
pended in the appropriate buffer prior to assay. The same
kits used for serum lipid analysis were used for analysis of
the extracts.
Intestinal alkaline phosphatase (IAP) activity was
assessed in protein extracts from 50 mg of jejunum tissue
using the SensoLyte pNPP Alkaline Phosphatase Assay Kit
(AnaSpec, Fremont, CA USA) following the manufac-
turer’s instructions. Data are expressed as microgram of
pNPP hydrolyzed per minute per milligram of protein.
Following the 24-week intervention, all mice were
analyzed in a Minispec mq benchtop NMR spectrom-
eter (Bruker Instruments) for fat and lean body mass.
Animals were then culled and tissues collected and
weighed.
Atherosclerotic plaque scoring
Atherosclerotic lesions were quantified by en face analysis
of the whole aorta. For the en face analysis of the aorta,
the aorta were paraformaldehyde (PFA) fixed (4% w/v) the
Oil-Red-O-stained aorta were photographed and used for
the quantification of atherosclerotic lesions [23]. The total
aortic surface area and the lesion area were measured by
image analysis (NIH ImageJ; version 1.49), and the ratio of
the lesion area to the total area was calculated.
Cecum microbiome
Microbial DNA was extracted from cecal content using
the QIAamp DNA Stool Mini Kit protocol (Qiagen),
adapted to include a bead-beating step. The V3-V4 re-
gions of the 16S gene were amplified using the primer
pair 5-TCGT CGGC AGCG TCAG ATGT GTAT
AAGA GACA GCCT ACGG GNGG CWGC AG-3 and
5-GTCT CGTG GGCT CGGA GATG TGTA TAAG
AGAC AGGA CTAC HVGG GTAT CTAA TCC-3, as
per the preparation instructions for Illumina MiSeq.
Samples were barcoded using the primer combinations
available in the Illumina Nextera kit (Illumina Nextera
XT, Illumina Sweden) prior to quantification with the
Qubit High Sensitivity DNA kit (Life Technologies),
equimolar pooling and high-throughput sequencing on
the MiSeq platform.
FLASH (FLASH: fast length adjustment of short reads
to improve genome assemblies) was applied for the as-
sembly of resulting 300-bp paired-end reads. Additional
sequence read processing, which included quality filter-
ing based on a quality score of >25 and removal of mis-
matched barcodes and sequences below length
thresholds, was performed within QIIME (version 1.8.0).
USEARCH (version 7, 64-bit) was utilized for denoising,
chimera detection, and clustering into operational taxo-
nomic units (OTUs) (97% identity). OTU sequences were
subsequently aligned using PyNAST (PyNAST: python
nearest alignment space termination), after which tax-
onomy was assigned at 97% similarity against the SILVA
SSURef database release 111. Alpha diversity estimates and
beta diversity were calculated using QIIME and principal
coordinate analysis (PCoA) plots were created in EMPeror
(version 0.9.3-dev; Emperor) and used to visualize differ-
ences in beta diversity based on UniFrac distances. Finally,
the Galaxy tool for determining the linear discriminant ana-
lysis (LDA) effect size (LEfSe) was used to identify taxa as-
sociated with particular interventions [24].
Cecum short-chain fatty acids—GC-MS
Between 50–100 mg of cecal content from each animal
were analyzed for SCFA composition as per the method
described in Patterson et al. [25]. Briefly, a predeter-
mined quantity of sample was vortexed with 1 ml of
HPLC-grade water and allowed to incubate at room
temperature for 10 min prior to centrifugation at
10,000 × g for 5 min. The supernatant was withdrawn
and 3 · 0 mM of the internal standard, 2-ethylbutyric
acid (Sigma Aldrich, Wicklow) was added. Samples were
passed through a 0 · 22 μm filter and transferred to clean
vials. Acetic, propionic, n-butyric, and butyric acids
(Sigma Aldrich, Wicklow) were used as standards. Sam-
ples were then analyzed on a Varian 3500 GC flame
ionization system, fitted with a Nukol-FFAP column
(30 × 0 · 32 × 0 · 25 mm; Sigma) under the conditions
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previously reported. SCFA quantities are expressed as
micromolar per gram cecum content.
Fecal metabolome—1H-NMR spectroscopy
Briefly, fecal samples were broken down under liquid ni-
trogen by pestle and mortar, and ~40 mg of ground
feces was weighted and transferred to microcentrifuge
tube. The sample was suspended in 500 μl of HPLC-
grade water by vortex mixing for 5 min at room
temperature, followed by 30-min shaking at 4 °C. The
suspension was then centrifuged at 22,400 × g for
30 min, at 4 °C. Supernatant was transferred to a new
microcentrifuge tube and this was centrifuged again
under the same conditions. Potassium buffer and D2O
were added to the supernatant and the mixture was
transferred to a clean NMR tube and analyzed on a
700 MHz Bruker NMR.
The resulting 1H-NMR spectra were processed and
analyzed using BAYESIL [26], a fully-automated NMR
spectral profiling program. A reference metabolite li-
brary was generated in the Chenomx NMR Suite Profes-
sional software package version 7.0 (Chenomx Inc.,
Edmonton, AB). The fits of a subset of the spectra were
then verified by comparison with Chenomx.
Serum metabolome—direct flow injection and LC-MS/MS
The serum collected as described previously was analyzed
using the Biocrates AbsoluteIDQ p180 Kit (BIOCRATES
Life Sciences AG, Austria), as described previously [27].
Following extraction and derivatization, analytes present
in the samples were detected and quantified on an ABI
4000 Q-Trap mass spectrometer (MDS Sciex) run in con-
junction with a reverse-phase HPLC-column. The analysis
revealed levels of a range of specific amino acids, biogenic
amines (BA), acylcarnitines (AC), lysophosphotidylcho-
lines (lysoPC), phosphotidylcholines (PC), sphingomyelins
(SM), and hexoses.
Statistical analysis
Biochemical and biometric data were analyzed by one-way
ANOVA against the HFC, performed in PASW Statistics
v18.0 (IBM Corp., Chicago, IL, USA). Finally, linear re-
gression was performed in Prism 5 (GraphPad Software
Inc., CA USA). 16S compositional sequencing and
metabolomics data were deemed to be non-normal and,
as a result, non-parametric analyses were performed. All
groups were analyzed by Kruskal-Wallis, followed by 2-
tailed Mann–Whitney U pairwise comparisons, solely be-
tween HFC and each other group.
MetaboAnalyst metabolomics analysis suite [28–30]
was utilized for normalization and multivariate analyses
of data. PERMANOVA analyses of all groups together
and direct comparisons of each treatment group against
the HFC were performed using Adonis [Vegan] [31] on
Bray-Curtis index of dissimilarity PCoA plot. Metabolo-
mic and microbiome data were Pareto scaled prior to
correlation analysis and plotting, while data were also
surveyed, and samples which did not have the complete
paired microbiome and relevant metabolome datasets
were removed prior to Procrustes and coinertia analysis.
For all analyses, a p value of less than 0.05 was consid-
ered to be statistically significant.
Results
Biochemical and biometric analysis
Animal body weights stratified the six groups into two
significantly separate clusters (p < 0.01); the high-weight
cluster which consists of PSE, HFC and BSH, and a low-
weight cluster consisting of STAT, OBG, and NC—named
in order of descending mean body weight (Fig. 1a). Both
OBG (p < 0.01) and STAT (p < 0.05) mice presented with
reduced percentage body fat when compared to the HFC
(Fig. 1b). Conversely, PSE animals displayed a significant
elevation in percentage body fat even when compared to
the HFC (p < 0.05; Fig. 1b). PSE mice presented with sig-
nificantly reduced total cholesterol when compared to the
HFC (p < 0.05; Fig. 1c). Intervention with OBG increased
HDL-C by ~100% when compared to the HFC (p < 0.01;
Fig. 1c), while no effect on LDL-C was observed in any of
the groups. Both OBG and STAT intervention sig-
nificantly reduced liver weights when compared to HFC
(p < 0.05; data not shown), while BSH and STAT reduced
liver triglyceride levels (p < 0.05; Fig. 1d). Circulating
triglyceride levels were found to be reduced only in OBG
treated animals (p < 0.05 Fig. 1d).
High-fat feeding significantly increased the expression
of IAP in the jejunum of all groups, bar OBG-fed mice,
when compared to NC mice (p < 0.05; Fig. 1f ). Further-
more, PSE mice were found to express the highest levels
of the enzyme, ~35 μg/min/mg proteins, which also
reached higher significance (p < 0.01).
Atherosclerotic plaque scoring
Intervention with PSE offered substantial protection
against the lipid-driven atherogenesis associated with the
apo-E−/− model, reducing total aortic plaque percentage
from 15.2% (HFC) to 2.4% (p < 0.001; Fig. 1e). While
OBG intervention reduced aortic plaque percentage to
7.4% (p < 0.05), neither of the other two interventions
significantly attenuated plaque formation. The NC-fed
group acted as a negative control for the function of the
model, demonstrating no plaque whatsoever.
Cecum microbiome compositional sequencing
NC animals scored higher than all other groups in each
diversity metric, bar Simpson—in which NC was solely
significantly higher than BSH (p < 0.05; Additional file 1:
Table S1). OBG and HFC displayed similar diversities;
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while PSE, BSH and STAT animals had further reduced
diversities compared to HFC for phylogenetic diversity
whole tree and observed species (p < 0.05). Interestingly,
there was a significant dissimilarity between groups
overall (p < 0.01) and each intervention apart from STAT
appeared to shift the microbiome β-diversity to such an
extent that they clustered away from that of the HFC
microbiome (Fig. 2a). However, PERMANOVA analysis
of Bray-Curtis index of dissimilarity revealed that solely
PSE clustered away from HFC significantly (p < 0.05),
while BSH was approaching significance (p = 0.07).
Fig. 2b depicts the taxa most associated with each of the
interventions and HFC, as determined by LEfSe.
Phylum-relative abundance analysis revealed a signifi-
cant increase in OBG (p < 0.01) and decrease in STAT
(p < 0.05) Verrucomicrobia levels when compared to
HFC (Additional file 1: Figure S1). Proteobacteria were
found to be elevated in the PSE animals when compared
Fig. 2 Effect of cardiovascular disease interventions on the microbiome composition. Unweighted unifrac principle coordinate analysis (PCoA)
plots (a), with linear discriminant analysis (LDA) effect size (LEfSe) representation of taxa associated with HFC and each intervention (b)
Fig. 1 Effect of cardiovascular disease interventions on adiposity, cholesterol and lipid profile, atherogenesis, and inflammation. a Animal weight
gain over the 24-week intervention period. b Percentage fat of animals prior to cull. c Serum total and HDL and LDL cholesterol evolution over 24-
week period. d Liver and serum triglyceride levels following intervention. e Aortic plaque as percentage of total area. f Intestinal alkaline phosphatase
(IAP) activity in jejunum tissue. g Positive correlation between visceral fat mass and IAP activity, with confidence bands displayed by dashed lines.
*(p < 0.05), **(p < 0.01), and ***(p < 0.001) represent significant differences when compared against HFC in one-way ANOVA. Plots depict significant
differences and plots depict individual replicates with mean and SEM
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to HFC (p < 0.01). This increase can be explained at the
genus level primarily by a significant increase in Helico-
bacter (p < 0.01) and Bilophila (p < 0.05; Additional file 1:
Figure S3). Finally, Deferribacteres were recorded at 0.9%
relative abundance in HFC; while not one NC animal har-
bored the phylum (p = 0.056), and only one animal of each
PSE (p < 0.05), OBG (p = 0.091), BSH (p = 0.075) and
STAT (p < 0.05) presented with the taxon.
At family level, a significant reduction in Streptococca-
ceae was recorded in PSE (p < 0.01), OBG (p < 0.01),
BSH (p < 0.05) and NC (p < 0.01). Peptostreptococcaceae
(p < 0.05) and Christenellaceae (p < 0.01) relative abun-
dances were reduced significantly in OBG and NC ani-
mals (Additional file 1: Figure S2). Desulfovibrionaceae
were elevated in BSH animals (p < 0.05), while the PSE
group displayed raised Bacteroidaceae (p < 0.01).
Hosted cecum and fecal metabolome
As anticipated, OBG mice displayed a SCFA profile most
similar to that of NC, with significantly increased n-
butyrate levels compared to HFC (p < 0.05; Fig. 3e).
Interestingly, however, PSE proved capable of influen-
cing acetate production most significantly when com-
pared to HFC (p < 0.05; Fig. 3e), while BSH and STAT
treatment appeared to have no detectable effect on these
bacterial fermentation products.
Univariate analysis of log-transformed mouse fecal
water metabolome data revealed a couple of interesting
functional fluctuations, which may have implications for
host cardiometabolic health. Intervention with PSE re-
sulted in significantly reduced levels of trimethylamine
(TMA) and isovalerate (p < 0.05). Supervised multivariate
analysis in the form of partial least squares discriminant
analysis (PLS-DA) and orthogonal PLS-DA (OPLS-DA)
was carried out. Solely OBG intervention altered the fecal
metabolome to cause clear cluster separation away from
HFC in OPLS-DA plots (Fig. 3b). PLS-DA provided lists
of metabolites that were found to be of most importance
in explaining differences between each intervention and
the HFC. PSE PLS-DA shifts were most strongly explained
by reduced levels of isovalerate (variable importance in
projection [VIP] score = 2.8) and TMA (VIP score = 2.2;
Additional file 1: Figure S4A). OBG-treated mice were as-
sociated with formate (VIP score = 2.5) and lactate (VIP
score = 2.1; Additional file 1: Figure S4B). In addition,
BSH intervention was associated with reduced TMA
(VIP score = 3.1) and elevated formate (VIP score = 3.0;
Additional file 1: Figure S4C), while STAT also appeared
to be associated most closely with formate (VIP score =
2.2; Additional file 1: Figure S4D). Finally, when the
microbiome compositional PCoA matrix was compared
with that of the fecal metabolome for each sample, we
found no significant correlation in their grouping dissimi-
larity (Mantel statistic r = 0.004585; p > 0.05).
Host serum metabolome
Analysis of the host serum lipid and AA metabolome re-
vealed several clear functional shifts in response to the
cardiovascular disease interventions, when compared to
the HFC. OPLS-DA plots depict clear cluster separation
of PSE (Fig. 4a) and OBG (Fig. 4b) away from the HFC.
PLS-DA important feature plots identified reduced PC aa
C30:2 as a very strong feature of the PSE mouse metabo-
lome (VIP score = 10.6; Additional file 1: Figure S4A). C3-
DC(C6-OH) was found to be of most importance in
explaining OBG serum metabolome PLS-DA shifts (VIP
score = 4.0; Additional file 1: Figure S4B). Finally, while
kynurenine was deemed to be the most important feature
in both BSH (VIP score = 7.0; Additional file 1: Figure
S4C) and STAT (VIP score = 3.9; Additional file 1: Figure
S4D), the relationship was negative in the latter. Interest-
ingly, comparison of the microbiome compositional PCoA
matrix with that of the fecal metabolome for each sample
revealed a significant correlation in group dissimilarity
(Mantel statistic r = 0.5013; p < 0.05).
In terms of specific amino acids, it was found that
OBG, BSH, and STAT all significantly reduced arginine
levels (p < 0.05), while NC increased ornithine (p < 0.05)
and BSH trended towards an increase (p = 0.09; Fig. 4e).
The biogenic amine creatine was significantly elevated
by PSE, OBG, and BSH interventions (p < 0.05; Fig. 4e).
No significant alterations to total amino acids, branched-
chain amino acids or total biogenic amines were observed
for any of the interventions or NC. In terms of AC, STAT
appeared to have a relatively profound effect (Fig. 4f),
significantly reducing C14:1-OH (i.e., hydroxytetr-
adecenoylcarnitine; p < 0.05), C18 (i.e., octadecanoylcarni-
tine; p < 0.05), C3 (i.e., propionylcarnitine; p < 0.05), C4
(i.e., butyrylcarnitine; p < 0.01), and C3-DC(C4-OH) (i.e.,
malonylcarnitine+3-hydroxybutyrylcarnitine; p < 0.05). PSE
was the only other intervention to impact on AC-
metabolism, also reducing C18 significantly (p < 0.05) and
trending towards a decrease in C3-DC(C4-OH) (p < 0.09).
Finally, solely PSE intervention also demonstrated an im-
pact on lysoPC and PC (Fig. 4g). The sterol intervention
significantly increased lysoPC a C26:0 (p < 0.05), lysoPC a
C28:1 (p < 0.05), PC aa C26:0 (p < 0.01), and PC aa C34:2
(p < 0.01), while decreasing PC ae C30:1 (p < 0.05) and abol-
ishing PC aa C30:2 levels entirely (p < 0.01).
Discussion
Although for many years the gut microbiome received lit-
tle or no recognition for its contribution to the efficacy of
certain functional food ingredients, we are now beginning
to appreciate its true influence [32]. Furthermore, due to
the broad metabolic capabilities of this microbial organ, it
is likely that gut bacteria could manipulate a portion of
the multitude of functional ingredients and drugs which
are currently approved by regulatory authorities but lack a
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well-defined mechanism of action [33]. In this study,
we aimed to characterize the effects of several com-
monly consumed nutritional cardiovascular disease in-
terventions currently available commercially, as well
as a widely prescribed statin, on the host and hosted
metabolome through targeted and non-targeted meta-
bolomic approaches, while also investigating the
effects on the microbiome composition through 16S
compositional sequencing.
PSE
PSE-intervened mice displayed perhaps the most inter-
esting physiological phenotype, with reduced cholesterol
and aortic plaque, but the highest body weight and
Fig. 3 Effect of cardiovascular disease interventions on the hosted cecal and fecal metabolome. Fecal metabolome OPLS-DA: a PSE (green) vs.
HFC (red). b OBG (green) vs. HFC (red). c BSH (red) vs. HFC (green). d STAT (green) vs. HFC (red). e Ceacum short-chain fatty acids (SCFA): Acetate
(brown), n-Butyrate (red) and Propionate (green) were quantified in cecal content extracts by GC-MS
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adiposity. The near complete eradication of aortic plaque
was also coupled with a significant decrease in fecal
TMA. Microbiome-derived TMA is known to pass into
host circulation and travel to hepatocytes, in which
flavin-containing monooxygenase-3 further metabolizes
the compound to trimethylamine-N-oxide (TMAO)
[2]—a process deemed to be highly correlated with
atherogenesis [34, 3]. In addition, we observed several
fascinating compositional microbiota fluctuations as a
result of the PSE intervention. These animals presented
with an elevated Helicobacter relative abundance, which
was raised to 4.5%, while the genus was not detected at
Fig. 4 Effect of cardiovascular disease interventions on the host serum metabolome. Serum metabolome OPLS-DA: a PSE (green) vs. HFC (red). b
OBG (green) vs. HFC (red). c BSH (red) vs. HFC (green). d STAT (green) vs. HFC (red). Significant differences in e amino acids and biogenic amines, f
acylcarnatines, and g phosphotidylcholines in serum from each group, as analyzed by DI and LC-MS/MS. *(p < 0.05) and **(p < 0.01) represent
significant differences when compared against HFC in one-way ANOVA. Plots depict individual replicates with mean and SEM
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significant levels in any other group. Although colonization
with Helicobacter can often remain harmless, the LPS and
other antigens associated with the genus have shown the
potential to induce a low-level systemic and vascular in-
flammatory tone in the host which may exacerbate athero-
genesis [35]. Moreover, current infections with Helicobacter
pylori have been associated with an altered, atherogenic
lipid profile [36]. Increased LPS levels in host circulation
characterize the low-level chronic inflammation, termed
metabolic endotoxaemia, which is associated with high fat-
induced metabolic dysfunction [37]. This scenario is
thought to occur through increased intestinal permeability,
which allows inflammatory bacterial fragments from the in-
testinal microbiota, such as LPS, to pass into circulation
[5]. Bates et al. [38] demonstrated that LPS exposure trig-
gered an increase in countervailing IAP expression, as the
enzyme acts to detoxify the contaminant by dephosphoryla-
tion of the highly inflammatory lipid A moiety. All high fat-
fed groups in this study, bar OBG, presented with elevated
IAP levels when compared to NC-fed mice. This coincides
with elevated Proteobacteria-relative abundances and vis-
ceral fat mass levels in these groups—effects from which
OBG mice appeared to be afforded protection. The present
study is possibly the longest run high fat-feeding trial avail-
able to report IAP levels in a mouse model, and thus, we
propose that animals experiencing the greatest level of
chronic endotoxemia may require augmentation of IAP ex-
pression to prevent low-level septicemia during high fat
consumption.
PSE mice also displayed significantly increased percent-
age body fat, ~20% compared to ~15% in HFC mice. To
date, there has been just one study reporting significant
weight gain in apo-E-deficient mice following consump-
tion of a phytosterol extract [39]. Erysipelotrichaceae, a
family of bacteria previously associated with high fat con-
sumption in murine models [40] and obesity in human co-
horts [41], were found to be elevated in PSE when
compared to HFC. Although each of the interventions ap-
peared to stimulate Erysipelotrichaceae levels, PSE dem-
onstrated the greatest propensity for this. This is peculiar,
as it contradicts a report of Martínez et al., in which a PSE
diet (5% w/w) was found to decrease Erysipelotrichaceae
abundance in hamsters [8]. However, PSE animals also
presented with elevated cecum acetate production and it
seems likely that a member of the Bacteroidaceae family
(such as Bacteroides or Parabacteroides [42]) may have
been responsible for the significant increase in acetate
production in PSE animals. SCFA are key microbial fer-
mentation metabolites which, through activation of G-
protein-coupled receptors (GPCR)-41 and 43, can have
important implications for host metabolic function [43].
However, the work of Turnbaugh et al. [44] a decade
ago highlighted an increased energy harvesting cap-
acity of the obesity-associated microbiota, which was
attributed most significantly to acetate production.
Taken together, these data may indicate a causative
role of the microbiome in the degree of adiposity of
PSE-treated animals.
Interestingly, while levels of the genus Roseburia—a
group of microbes which express butyryl-coenzyme A,
an enzyme involved in the conversion of acetate to
butyrate—were increased >250% in the PSE mice
compared to HFC, the ratio of acetate:butyrate remained
high. Roseburia spp. have also been proven to
metabolize linoleic acid into two precursors of the c9,
t11-conjugated linoleic acid (CLA) isomer [45], a
bacterial metabolite which has shown potential in the
attenuation of inflammatory disorders such as cardio-
vascular disease [46]. Finally, PSE mice were again
found to be unique in that they displayed an altered
PC and LysoPC profile. This is certainly interesting,
as PSE are known to interact with PC, while directly
competing with cholesterol in the formation of biliary
micelles [47].
OBG
Butyrate levels were found to be elevated in cecal con-
tent of OBG-treated mice, suggesting a prebiotic effect.
In contrast to acetate, butyrate and propionate have pre-
viously been found to protect against diet-induced obes-
ity in a murine model [48], which may explain the body
weight and percentage fat displayed by OBG-intervened
mice. In addition, this increase in butyrate could also ex-
plain the prevention of IAP expression increase observed
in all other high fat-fed groups, as the SCFA has been
shown to have important implications for tight-junction
function in the gut barrier [43, 49]. As anticipated, OBG
intervention again appeared to exhibit prebiotic effects
on the cecal microbiota through stimulation of Verruco-
microbia population expansion. Akkermansia, the sole
identified gut microbiota member genus of the phylum
Verrucomicrobia [50], has been shown to have major im-
plications for host metabolic health, including metabolic
endotoxaemia [51–53]. While prebiotic-mediated pro-
motion of Akkermansia muciniphila levels has displayed
great potential in stimulating gut peptide production
[51], thereby improving tight junction function and insu-
lin sensitivity [13], it is also a potent mucin degrader—a
process in which sulfate is released as a by-product [54].
The elevated levels of Akkermansia in the OBG-treated
animals therefore most likely explain the simultaneous
expansion of sulfate-reducing Desulfovibrio populations,
as has previously been observed in a healthy adolescent
human cohort [55]. Desulfovibrio spp. display a relatively
unique and potentially harmful metabolic profile, redu-
cing sulfates to potentially carcinogenic sulfides [56] and
catabolizing choline to potentially atherogenic TMA
[57]. Interesting in this regard was the fact that OBG-
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intervened mice demonstrated the highest mean fecal
TMA levels; however, this was not significantly higher
than HFC animals. Despite this, OBG mice appeared
to be protected from the high-fat/cholesterol-induced
atherogenesis. Moreover, in the previous mentioned
adolescent study, both Akkermansia and Desulfovibrio
levels were associated with the healthy control cohort
rather than the obese/overweight group [55].
BSH
VSL#3 is a probiotic mix of bifidobacteria, lactobacilli,
and streptococci cultures which has displayed BSH activ-
ity in vivo [58]. While the BSH-active Lactobacillus reu-
teri investigated in this study was associated with
increased Verrucomicrobia levels, when VSL#3 was ap-
plied to a murine model of colonic cancer the luminal
and mucosal-adherent levels of the phylum were greatly
reduced [59]. As with OBG intervention, this increase in
Verrucomicrobia was again associated with an increase
in Desulfovibrionaceae. However, the expansion of OBG
Desulfovibrionaceae levels was solely the result of in-
creased Desulfovibrio, in contrast with BSH animals
there was no such effect on the TMA-producing gen-
us—perhaps explaining the lack of increase in
proatherogenic metabolites in these animals. In fact,
the increase was due to raised levels of taurine-
degrading bacterium, Bilophila [60]. High fat consump-
tion has previously been shown to increase levels of the
pathobiont Bilophila wadsworthia [61], although the
same effect has also been achieved by increasing host
tauro-conjugated bile acid levels. This makes it particu-
larly interesting that the genus was increased in the
BSH group in the present study, when compared to the
control. A recent clinical study investigating the effects
of daily consumption of BSH-active Lb. reuteri NCIMB
30242 in a delayed release capsule uncovered a signifi-
cant and sustained increase in both glyco and tauro-
conjugated bile acid levels over a 4-week intervention
period in otherwise healthy, hypercholesterolemic sub-
jects [62]. The implications of such a fluctuation to
host cardiovascular disease risk are currently unclear;
however, it may be important to consider how BSH
intervention may affect populations of this potentially
inflammatory pathobiont in the human intestinal
microbiota.
STAT
Simvastatin is an example of a cardiovascular disease drug
which modulates gut microbiota composition [63] and
whose efficacy appears to rely on a suitably responsive
microbiome [64]. Simvastatin has previously been shown
to boost Lactobacillus populations, while in the present
study Atorvastatin showed little global effect (Fig. 2a).
However, the STATgroup was the only intervention group
to display an increase in Ruminococcus-relative abundance
(of ~50%) when compared to HFC-fed animals. Certain
Ruminococcus spp. have been described as key-stone spe-
cies in the catabolism of resistant starch [65] and mucin
[66]; and therefore promote a diverse, saccharolytic micro-
biota which may have implications for host metabolic
health. Despite having only a modest effect on micro-
biome composition and functionality, STAT appeared
to shift the host serum AC composition, reducing the
levels of several of these molecules which play central
roles in lipid metabolism. In line with this, serum AC
concentrations have been positively correlated with
obesity and other metabolic dysfunctions [67]. Fur-
thermore, several of the same AC which were reduced
by STAT intervention have previously been positively
associated with glucose intolerance in prediabetic and
type-2 diabetic cohorts [68]. Intriguingly, STAT
animal physiology was most similar to that of OBG
animals—presenting with reduced liver weight, body
weight, and a near significant reduction in percentage
body fat—potentially as a direct result of these AC-
modifying attributes. Despite all of these metabolism-
linked alterations, no attenuation effect on atherogenic
plaque development was noted following STAT interven-
tion. This is not surprising given that previous work
failed to demonstrate an ability of a Simvastatin-based
intervention to prevent plaque development in the same
murine model [69].
Conclusions
This study has highlighted the impact of commonly con-
sumed nutritional and pharmaceutical cardiovascular
disease interventions on the gut microbiome. In particu-
lar, the data show disconnect between weight gain and
adiposity versus atherogenic plaque development in
PSE-intervened mice, which is intriguing. This observa-
tion coincided with reductions of proatherogenic and
metabolism-modulating microbial metabolites in fecal
water, and the greatest alterations in microbiome com-
position relative to the HFC. In addition, we demon-
strate the impact of these alterations on the host serum
metabolome, in the context of cardiometabolic function.
Overall, OBG intervention caused the most favorable
shifts in microbiome composition and functionality,
which may have contributed to the healthy phenotype
observed in this group. On balance, it appears that OBG
may be the preferred dietary intervention for safe long-
term maintenance of cardiovascular and metabolic
health, potentiated by the microbiota. As novel thera-
peutics enter the market, it becomes increasingly im-
portant that we consider their effects on our microbial
organ and disentangle direct drug actions from drug-
microbiome mediated actions.
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Additional file 1: Figure S1. Phylum-relative abundances of intervention
and control groups. (i) Phylum-relative abundances, with inset plots
representing phyla in which a significant difference between HFC
and another group has been identified. *(p < 0.05) and **(p < 0.01)
represent significant differences recorded between HFC and one of
the interventions, or NC. Plots depict individual replicates with mean and
SEM. Figure S2. Family-relative abundances of intervention and control
groups. *(p < 0.05) and **(p < 0.01) represent significant differences
recorded between HFC and one of the interventions, or NC. Plots
depict individual replicates with mean and SEM. Figure S3. Genus-relative
abundances of intervention and control groups. Genus-relative abundances,
with inset plots representing genera in which a significant difference between
HFC and another group have been identified. *(p< 0.05) and **(p< 0.01)
represent significant differences recorded between HFC and one of the
interventions, or NC. Plots depict individual replicates with mean and SEM.
Figure S4. Fecal metabolome important features associated with each cardio-
vascular disease intervention. The fecal metabolites found to be the most
important in explaining shifts in PLS-DA for each intervention (PSE [A], OBG
[B], BSH [C], and STAT [D]) when compared to the HFC. Figure S5. Serum
metabolome important features associated with each cardiovascular disease
intervention. The serum metabolites found to be most important in explaining
shifts in PLS-DA for each intervention (PSE [A], OBG [B], BSH [C], and STAT [D])
when compared to the HFC. Figure S6. Correlation heatmap containing
physiological, microbiome, and fecal metabolome data. Figure S7. Correlation
coefficient analysis plots of primary physiological outcomes with microbiome
and fecal metabolome. Several important metabolic markers are displayed
with the microbial taxa and metabolites most correlated (Cholesterol [A],
Plaque [B], TAG [C], and IAP [D]). *FDR-adjusted p< 0.05. Table S1. Alpha
diversity of intervention and control groups. Means in a row with common
superscripts do not differ (p≥ 0.05). (DOCX 2462 kb)
Abbreviations
AC: Acylcarnitines; BSH: Bile salt hydrolase; CLA: Conjugated linoleic acid;
GLP-1: Glucagon-like peptide-1; GLP-1R: Glucagon-like peptide-1 receptor;
GPCR: G-protein-coupled receptor; HDL-C: High-density lipoprotein
cholesterol; HFC: High-fat/cholesterol control; IAP: Intestinal alkaline
phosphatase; LDA: Linear discriminant analysis; LDL-C: Low-density
lipoprotein cholesterol; LEfSe: Linear discriminant analysis effect size;
lysoPC: Lysophosphotidylcholines; MRS: De Man Rugosa Sharp; NC: Normal
chow; OBG: Oat β-glucan; OPLS-DA: Orthogonal partial least squares
discriminant analysis; OTU: Operational taxonomic units;
PC: Phosphotidylcholines; PCoA: Principal coordinate analysis;
PFA: Paraformaldehyde; PLS-DA: Partial least squares discriminant analysis;
PSE: Plant sterol ester; PYY: Peptide YY; SM: Sphingomyelins; STAT: Statin;
TG: Triglycerides; TMA: Trimethylamine; TMAO: Trimethylamine-N-oxide;
VIP: Variable importance in projection.
Acknowledgements
The authors wish to thank Dr. Kenneth Martin, Dr. Elaine Patterson, Mr.
Calum Walsh, and Ms. Elaine O’ Brien for their technical assistance during the
study. Finally, we extend our gratitude to Clinical-Microbiomics (Kogle Allé 5,
DK-2970 Hørsholm, Denmark) for their sequencing services and excellent
technical assistance.
Funding
Paul M. Ryan is in receipt of a Teagasc Walsh Fellowship. Travel support was
awarded to Paul M. Ryan by the Ireland Canada University Foundation (ICUF)
Dobbin Scholarship and the Teagasc Walsh Fellow Short-term Overseas Training
Scheme for work carried out in The Metabolomics Innovation Centre (TMIC), Uni-
versity of Alberta. This work is supported by The APC Microbiome Institute (under
Science Foundation Ireland [SFI] grant number: SFI/12/RC/2273) and by Enterprise
Ireland Commercialization Fund (contract reference: CF/2013/3030A/B).
Availability of data and materials
Raw data can be obtained from the Sequence Read Archive, under
BioProject accession number PRJNA371720.
Authors’ contributions
RPR, GFF, NMC, FS and CS designed research. PMR, LEEL, and TCB conducted
research. DSW provided essential reagents or provided essential materials. PMR,
KM, and RM analyzed data. PMR, NMC, and CS wrote the paper. CS and NMC
had primary responsibility for final content. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval
The use and care of animals was carried out in accordance with protocols
approved by the Ethics Committee, University College Cork, under a license
issued by the Department of Health and Children (Cruelty to Animal Act
1876, Directive for the Protection of Vertebrate Animals used for
Experimental and other Scientific Purposes).
Author details
1Department of Food Biosciences, Teagasc Food Research Centre,
Moorepark, Fermoy, Co. Cork, Ireland. 2School of Microbiology, University
College Cork, Co. Cork, Ireland. 3Department of Biological Sciences, University
of Alberta, Edmonton, AB, Canada. 4Department of Medicine, University
College Cork, National University of Ireland, Cork, Ireland. 5APC Microbiome
Institute, Biosciences Institute, University College Cork, Co. Cork, Ireland.
6College of Science, Engineering & Food Science, University College Cork, Co.
Cork, Ireland. 7Department of Computing Science, University of Alberta,
Edmonton, AB, Canada. 8National Institute for Nanotechnology, Edmonton,
AB, Canada. 9Centre for Research in Vascular Biology, University College Cork,
Co. Cork, Ireland.
Received: 20 July 2016 Accepted: 23 February 2017
References
1. WHO. Global status report on noncommunicable diseases The World Health
Organisation; 2014.
2. Warrier M, Shih DM, Burrows AC, Ferguson D, Gromovsky AD, Brown AL,
Marshall S, McDaniel A, Schugar RC, Wang Z, et al. The TMAO-Generating
Enzyme Flavin Monooxygenase 3 Is a Central Regulator of Cholesterol
Balance. Cell Rep. 2015;10(3):326–338.
3. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y,
Li L, et al. Intestinal microbiota metabolism of l-carnitine, a nutrient in red
meat, promotes atherosclerosis. Nat Med. 2013;19(5):576–85.
4. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J,
Allayee H, Lee R, Graham M, Crooke R. Trimethylamine-N-oxide, a
metabolite associated with atherosclerosis, exhibits complex genetic and
dietary regulation. Cell Metab. 2013;17(1):49–60.
5. Cani PD, Bibiloni R, Knauf C, Neyrinck AM, Neyrinck AM, Delzenne NM,
Burcelin R. Changes in gut microbiota control metabolic endotoxemia-
induced inflammation in high-fat diet-induced obesity and diabetes in
mice. Diabetes. 2008;57(6):1470–81.
6. Cani PD, Geurts L, Matamoros S, Plovier H, Duparc T. Glucose metabolism:
focus on gut microbiota, the endocannabinoid system and beyond.
Diabetes Metab. 2014;40(4):246–57.
7. Ryan PM, Ross RP, Fitzgerald GF, Caplice NM, Stanton C. Functional food
addressing heart health: do we have to target the gut microbiota? Curr
Opin Clin Nutr Metab Care. 2015;18(6):566–71.
8. Martinez I, Perdicaro DJ, Brown AW, Hammons S, Carden TJ, Carr TP,
Eskridge KM, Walter J. Diet-induced alterations of host cholesterol
metabolism are likely to affect the gut microbiota composition in hamsters.
Appl Environ Microbiol. 2013;79(2):516–24.
9. Flint HJ, Scott KP, Duncan SH, Louis P, Forano E. Microbial degradation of
complex carbohydrates in the gut. Gut Microbes. 2012;3(4):289–306.
10. Bach Knudsen KE. Microbial degradation of whole-grain complex
carbohydrates and impact on short-chain fatty acids and health. Advanc
Nutr. 2015;6(2):206–13.
Ryan et al. Microbiome  (2017) 5:30 Page 11 of 13
11. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The
gastrointestinal microbiota as a site for the biotransformation of drugs. Int J
Pharm. 2008;363(1–2):1–25.
12. Lee H, Ko G. Effect of metformin on metabolic improvement and gut
microbiota. Appl Environ Microbiol. 2014;80(19):5935–43.
13. Everard A, Lazarevic V, Derrien M, Girard M, Muccioli GG, Neyrinck AM,
Possemiers S, Van Holle A, François P, de Vos WM. Responses of gut
microbiota and glucose and lipid metabolism to prebiotics in genetic obese
and diet-induced leptin-resistant mice. Diabetes. 2011;60(11):2775–86.
14. Whitehead A, Beck EJ, Tosh S, Wolever TM. Cholesterol-lowering effects of
oat β-glucan: a meta-analysis of randomized controlled trials. Am J Clin
Nutr. 2014;100(6):1413–21.
15. Ho HV, Sievenpiper JL, Zurbau A, Blanco Mejia S, Jovanovski E,
Au-Yeung F, Jenkins AL, Vuksan V. The effect of oat beta-glucan on
LDL-cholesterol, non-HDL-cholesterol and apoB for CVD risk reduction: a
systematic review and meta-analysis of randomised-controlled trials. Br J
Nutr. 2016;116(8):1369–82.
16. Wang Y, Ames NP, Tun HM, Tosh SM, Jones PJ, Khafipour E. High molecular
weight barley β-glucan alters gut microbiota toward reduced cardiovascular
disease risk. Front Microbiol. 2016;7:129.
17. Joyce SA, Gahan CG. Bile Acid Modifications at the Microbe-Host Interface:
Potential for Nutraceutical and Pharmaceutical Interventions in Host Health.
Annu Rev Food Sci Technol. 2016;7:313–33.
18. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C,
Gahan CGM. Regulation of host weight gain and lipid metabolism by bacterial
bile acid modification in the gut. Proc Natl Acad Sci. 2014;111(20):7421–6.
19. Jones ML, Martoni CJ, Prakash S. Cholesterol lowering and inhibition of
sterol absorption by Lactobacillus reuteri NCIMB 30242: a randomized
controlled trial. Eur J Clin Nutr. 2012;66(11):1234–41.
20. Jones ML, Martoni CJ, Parent M, Prakash S. Cholesterol-lowering efficacy of a
microencapsulated bile salt hydrolase-active Lactobacillus reuteri NCIMB
30242 yoghurt formulation in hypercholesterolaemic adults. Br J Nutr. 2012;
107(10):1505–13.
21. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein
E knockout models. Curr Pharm Des. 2008;14(4):338–51.
22. Folch J, Lees M, Sloane-Stanley G. A simple method for the isolation and
purification of total lipids from animal tissues. J Biol Chem. 1957;226(1):497–509.
23. Koga M, Kai H, Yasukawa H, Yamamoto T, Kawai Y, Kato S, Kusaba K, Kai M,
Egashira K, Kataoka Y, et al. Inhibition of progression and stabilization of
plaques by postnatal interferon-gamma function blocking in ApoE-knockout
mice. Circ Res. 2007;101(4):348–56.
24. Segata N, Izard J, Waldron L, Gevers D, Miropolsky L, Garrett WS,
Huttenhower C. Metagenomic biomarker discovery and explanation.
Genome Biol. 2011;12(6):R60.
25. Patterson E, O' Doherty RM, Murphy EF, Wall R, O' Sullivan O, Nilaweera K,
Fitzgerald GF, Cotter PD, Ross RP, Stanton C. Impact of dietary fatty acids on
metabolic activity and host intestinal microbiota composition in C57BL/6 J
mice. Brit J Nutr. 2014;111(11):1905–17.
26. Buglioni A, Burnett Jr JC. A gut-heart connection in cardiometabolic
regulation. Nat Med. 2013;19(5):534–6.
27. Walsh BH, Broadhurst DI, Mandal R, Wishart DS, Boylan GB, Kenny LC,
Murray DM. The metabolomic profile of umbilical cord blood in neonatal
hypoxic ischaemic encephalopathy. PLoS One. 2012;7(12):e50520.
28. Fernandes J, Wang A, Su W, Rozenbloom SR, Taibi A, Comelli EM, Wolever TM.
Age, dietary fiber, breath methane, and fecal short chain fatty acids are
interrelated in Archaea-positive humans. J Nutr. 2013;143(8):1269–75.
29. Jarrell KF, Walters AD, Bochiwal C, Borgia JM, Dickinson T, Chong JP. Major
players on the microbial stage: why archaea are important. Microbiology.
2011;157(4):919–36.
30. Pimentel M, Gunsalus RP, Rao SS, Zhang H. Methanogens in human health
and disease. Am J Gastroenterol Suppl. 2012;1(1):28–33.
31. Oksanen J, Kindt R, Legendre P, O’Hara B, Stevens MHH, Oksanen MJ,
Suggests M.The vegan package. Community Ecol Package. 2007;10.
32. Laparra JM, Sanz Y. Interactions of gut microbiota with functional food
components and nutraceuticals. Pharmacol Res. 2010;61(3):219–25.
33. Gregori-Puigjane E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett
L, Roth BL, Shoichet BK. Identifying mechanism-of-action targets for drugs
and probes. Proc Natl Acad Sci U S A. 2012;109(28):11178–83.
34. Tang WHW, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL.
Intestinal microbial metabolism of phosphatidylcholine and cardiovascular
risk. N Engl J Med. 2013;368(17):1575–84.
35. Oshima T, Ozono R, Yano Y, Oishi Y, Teragawa H, Higashi Y, Yoshizumi M,
Kambe M. Association of Helicobacter pylori infection with systemic
inflammation and endothelial dysfunction in healthy male subjects. J Am
Coll Cardiol. 2005;45(8):1219–22.
36. Hoffmeister A, Rothenbacher D, Bode G, Persson K, März W, Nauck MA,
Brenner H, Hombach V, Koenig W. Current infection with Helicobacter
pylori, but not seropositivity to Chlamydia pneumoniae or cytomegalovirus,
is associated with an atherogenic, modified lipid profile. Arterioscler Thromb
Vasc Biol. 2001;21(3):427–32.
37. Cani PD, Amar J, Iglesias MA, Poggi M, Knauf C, Bastelica D, Neyrinck AM,
Fava F, Tuohy KM, Chabo C, et al. Metabolic endotoxemia initiates obesity
and insulin resistance. Diabetes. 2007;56(7):1761–72.
38. Bates JM, Akerlund J, Mittge E, Guillemin K. Intestinal alkaline phosphatase
detoxifies lipopolysaccharide and prevents inflammation in zebrafish in
response to the gut microbiota. Cell Host Microbe. 2007;2(6):371–82.
39. Moghadasian MH, McManus BM, Pritchard PH, Frohlich JJ. “Tall
Oil”—derived phytosterols reduce atherosclerosis in ApoE-deficient mice.
Arterioscler Thromb Vasc Biol. 1997;17(1):119–26.
40. Turnbaugh PJ, Backhed F, Fulton L, Gordon JI. Diet-induced obesity is linked
to marked but reversible alterations in the mouse distal gut microbiome.
Cell Host Microbe. 2008;3(4):213–23.
41. Zhang H, DiBaise JK, Zuccolo A, Kudrna D, Braidotti M, Yu Y, Parameswaran
P, Crowell MD, Wing R, Rittmann BE. Human gut microbiota in obesity and
after gastric bypass. Proc Natl Acad Sci. 2009;106(7):2365–70.
42. Nelson MC, Morrison M, Yu Z. A meta-analysis of the microbial diversity
observed in anaerobic digesters. Bioresour Technol. 2011;102(4):3730–9.
43. Peng L, Li ZR, Green RS, Holzman IR, Lin J. Butyrate enhances the intestinal
barrier by facilitating tight junction assembly via activation of AMP-activated
protein kinase in Caco-2 cell monolayers. J Nutr. 2009;139(9):1619–25.
44. Turnbaugh PJ, Ley RE, Mahowald MA, Magrini V, Mardis ER, Gordon JI. An
obesity-associated gut microbiome with increased capacity for energy
harvest. Nature. 2006;444(7122):1027–31.
45. Devillard E, McIntosh FM, Duncan SH, Wallace RJ. Metabolism of linoleic
acid by human gut bacteria: different routes for biosynthesis of conjugated
linoleic acid. J Bacteriol. 2007;189(6):2566–70.
46. Viladomiu M, Hontecillas R, Bassaganya-Riera J. Modulation of inflammation and
immunity by dietary conjugated linoleic acid. Eur J Pharmacol. 2016;785:87–95.
47. Aminov RI. Role of archaea in human disease. Front Cell Infect
Microbiol. 2013;3:42.
48. Lin HV, Frassetto A, Kowalik Jr EJ, Nawrocki AR, Lu MM, Kosinski JR, Hubert
JA, Szeto D, Yao X, Forrest G, et al. Butyrate and propionate protect against
diet-induced obesity and regulate gut hormones via free fatty acid receptor
3-independent mechanisms. PLoS One. 2012;7(4):e35240.
49. Wang H-B, Wang P-Y, Wang X, Wan Y-L, Liu Y-C. Butyrate enhances
intestinal epithelial barrier function via up-regulation of tight junction
protein Claudin-1 transcription. Dig Dis Sci. 2012;57(12):3126–35.
50. Derrien M, Collado MC, Ben-Amor K, Salminen S, de Vos WM. The mucin
degrader Akkermansia muciniphila is an abundant resident of the human
intestinal tract. Appl Environ Microbiol. 2008;74(5):1646–8.
51. Everard A, Belzer C, Geurts L, Ouwerkerk JP, Druart C, Bindels LB, Guiot Y,
Derrien M, Muccioli GG, Delzenne NM, et al. Cross-talk between
Akkermansia muciniphila and intestinal epithelium controls diet-induced
obesity. Proc Natl Acad Sci. 2013;110(22):9066–71.
52. Lukovac S, Belzer C, Pellis L, Keijser BJ, de Vos WM, Montijn RC, Roeselers G.
Differential modulation by Akkermansia muciniphila and Faecalibacterium
prausnitzii of host peripheral lipid metabolism and histone acetylation in
mouse gut organoids. mBio. 2014;5(4):e01438–14.
53. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. An
increase in the Akkermansia spp. population induced by metformin
treatment improves glucose homeostasis in diet-induced obese mice.
Gut. 2014;63(5):727–35.
54. Derrien M, Vaughan EE, Plugge CM, de Vos WM. Akkermansia muciniphila
gen. nov., sp. nov., a human intestinal mucin-degrading bacterium. Int J
Syst Evol Microbiol. 2004;54(Pt 5):1469–76.
55. Karlsson CL, Onnerfalt J, Xu J, Molin G, Ahrne S, Thorngren-Jerneck K. The
microbiota of the gut in preschool children with normal and excessive
body weight. Obesity. 2012;20(11):2257–61.
56. Oliveira TF, Vonrhein C, Matias PM, Venceslau SS, Pereira IAC, Archer M. The
crystal structure of Desulfovibrio vulgaris dissimilatory sulfite reductase
bound to DsrC provides novel insights into the mechanism of sulfate
respiration. J Biol Chem. 2008;283(49):34141–9.
Ryan et al. Microbiome  (2017) 5:30 Page 12 of 13
57. Craciun S, Balskus EP. Microbial conversion of choline to trimethylamine
requires a glycyl radical enzyme. Proc Natl Acad Sci. 2012;109(52):21307–12.
58. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. Microbiota
modification with probiotics induces hepatic bile acid synthesis via
downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014;7(1):12–8.
59. Arthur JC, Gharaibeh RZ, Uronis JM, Perez-Chanona E, Sha W, Tomkovich S,
Mühlbauer M, Fodor AA, Jobin C. VSL# 3 probiotic modifies mucosal
microbial composition but does not reduce colitis-associated colorectal
cancer. Sci Rep. 2013;3:2868.
60. Laue H, Friedrich M, Ruff J, Cook AM. Dissimilatory sulfite reductase
(desulfoviridin) of the taurine-degrading, non-sulfate-reducing bacterium
Bilophila wadsworthia RZATAU contains a fused DsrB-DsrD subunit. J
Bacteriol. 2001;183(5):1727–33.
61. Devkota S, Wang Y, Musch MW, Leone V, Fehlner-Peach H, Nadimpalli A,
Antonopoulos DA, Jabri B, Chang EB. Dietary-fat-induced taurocholic acid
promotes pathobiont expansion and colitis in Il10−/− mice. Nature. 2012;
487(7405):104–8.
62. Martoni CJ, Labbé A, Ganopolsky JG, Prakash S, Jones ML. Changes in bile
acids, FGF-19 and sterol absorption in response to bile salt hydrolase active
L. reuteri NCIMB 30242. Gut Microbes. 2015;6(1):57–65.
63. Catry E, Pachikian BD, Salazar N, Neyrinck AM, Cani PD, Delzenne NM.
Ezetimibe and simvastatin modulate gut microbiota and expression of
genes related to cholesterol metabolism. Life Sci. 2015;132:77–84.
64. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng Z-B, Wiest MM, Nguyen UT,
Wojnoonski K, Watkins SM, Trupp M, Krauss RM. Enteric microbiome
metabolites correlate with response to simvastatin treatment. PLoS One.
2011;6(10):e25482.
65. Ze X, Duncan SH, Louis P, Flint HJ. Ruminococcus bromii is a keystone
species for the degradation of resistant starch in the human colon. ISME J.
2012;6(8):1535–43.
66. Crost EH, Tailford LE, Le Gall G, Fons M, Henrissat B, Juge N. Utilisation of
mucin glycans by the human gut symbiont Ruminococcus gnavus is strain-
dependent. PLoS One. 2013;8(10):e76341.
67. Mihalik SJ, Goodpaster BH, Kelley DE, Chace DH, Vockley J, Toledo FG,
DeLany JP. Increased levels of plasma acylcarnitines in obesity and type 2
diabetes and identification of a marker of glucolipotoxicity. Obesity. 2010;
18(9):1695–700.
68. Mai M, Tönjes A, Kovacs P, Stumvoll M, Fiedler GM, Leichtle AB. Serum
levels of acylcarnitines are altered in prediabetic conditions. PLoS One.
2013;8(12):e82459.
69. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME.
Simvastatin promotes atherosclerotic plaque stability in apoE-deficient
mice independently of lipid lowering. Arterioscler Thromb Vasc Biol.
2002;22(11):1832–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Ryan et al. Microbiome  (2017) 5:30 Page 13 of 13
